Lu et al. found that the Nrf2 inhibitor, brusatol, downregulated HIF-1α at the protein level in colon cancer cells by promoting its proteasomal degradation, and this suppressed glucose uptake in these cells [155], suggesting the therapeutic potential of Nrf2 inhibitors in targeting this mechanism of hypoxia-induced chemoresistance. This evidence concerns the gene HIF1A and colonic neoplasm.